Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Jan 16;36(23):3274–3286. doi: 10.1038/onc.2016.472

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2017 The Author(s)

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/

PMC Copyright notice

Nutlin-3 treatment stabilizes Mdm2 and downregulates IGF-1R. (a) Mdm2 functional and binding domains. Diagram indicating the known functional domains and the limits of regions interacting with Nutlin-3 and β-arr1/IGF-1R. (b–d) Dose (b) and time (c) dependent effects of Nutlin-3 treatment on p53, Mdm2 and IGF-1R expression. Cells incubated in serum were treated with Nutlin-3 as indicated. Protein lysates were analyzed by WB for IGF-1R, p53, Mdm2 and GAPDH as a loading control (left panels). IGF-1R signals were quantified by densitometry, normalized to GAPDH and expressed as a percentage of the IGF-1R in the control-treated cells (right panels). Data correspond to the mean±s.e.m. from three independent experiments. Statistical analysis: Nutlin-3-treated cells compared with control-treated cells: *P<0.05, **P<0.01.